{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:52:33Z","timestamp":1787007153539,"version":"build-2736575974"},"reference-count":119,"publisher":"Informa UK Limited","issue":"10","funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research","doi-asserted-by":"crossref","award":["CSIR;02(0319)17\/EMR"],"award-info":[{"award-number":["CSIR;02(0319)17\/EMR"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Rajiv Gandhi National Fellowship","award":["F1-17.1\/2017-18\/RGNF-2017-18-SC-PUN-33911"],"award-info":[{"award-number":["F1-17.1\/2017-18\/RGNF-2017-18-SC-PUN-33911"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2020,10,2]]},"DOI":"10.1080\/13543776.2020.1811233","type":"journal-article","created":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T06:37:13Z","timestamp":1597559833000},"page":"769-780","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":57,"title":["Xanthine oxidase inhibitors: patent landscape and clinical development (2015\u20132020)"],"prefix":"10.1080","volume":"30","author":[{"given":"Jatinder Vir","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preet Mohinder Singh","family":"Bedi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harbinder","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"key":"e_1_3_4_3_1","first-page":"2158","volume-title":"Harrison\u2019s principles of internal medicine","author":"Wortmann RL.","year":"1998","unstructured":"Wortmann RL. Gout and other disorders of purine metabolism. In: Brunwald E, editor. Harrison\u2019s principles of internal medicine. 14th ed. New York (NY): McGraw-Hill; 1998. p. 2158\u20132166.","edition":"14"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.32"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21457"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature742"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2011.577417"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780341203"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199345020-00004"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.1.6"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199305040-00017"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.1999.10.1.706"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s100670050005"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200005000-00010"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2017.1261111"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja027388d"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.9.11.7649415"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a124480"},{"key":"e_1_3_4_19_1","doi-asserted-by":"crossref","first-page":"14170","DOI":"10.1016\/S0021-9258(18)77283-9","article-title":"Proteolytic conversion of xanthine dehydrogenase from the NAD-dependent type to the O2-dependent type. Amino acid sequence of rat liver xanthine dehydrogenase and identification of the cleavage sites of the enzyme protein during irreversible conversion by trypsin","volume":"265","author":"Amaya Y","year":"1990","unstructured":"Amaya Y, Yamazaki K, Sato M, et al. Proteolytic conversion of xanthine dehydrogenase from the NAD-dependent type to the O2-dependent type. Amino acid sequence of rat liver xanthine dehydrogenase and identification of the cleavage sites of the enzyme protein during irreversible conversion by trypsin. J Biol Chem. 1990;265:14170\u201314175.","journal-title":"J Biol Chem"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0400973101"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.20.10723"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja1077574"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.128561"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)62884-4"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2015.01.022"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.08.011"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.07.041"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/15257770802146577"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.14.7816"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/np500320g"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4838(99)00023-0"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-827X(01)01160-0"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1039\/a907673e"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.33.3113"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1039\/c39950002041"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10822-009-9314-z"},{"key":"e_1_3_4_37_1","first-page":"135","volume-title":"Purine and pyrimidine metabolism in man VII, Volume 309A of the series advances in experimental medicine and biology","author":"Seiji S","year":"1991","unstructured":"Seiji S, Kunihiko T, Takeshi N. A novel xanthine dehydrogenase inhibitor (BOF-4272). In: Harkness RA, Elion GB, Zollner N, editors. Purine and pyrimidine metabolism in man VII, Volume 309A of the series advances in experimental medicine and biology. New York. (US): Springer; 1991. p. 135\u2013138."},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831080-00002"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M208307200"},{"key":"e_1_3_4_40_1","first-page":"S531","article-title":"Effect of febuxostat, a novel nonpurine, selective inhibitor of xanthine oxidase (NP-SIXO), on enzymes in purine and pyrimidine metabolism pathway","volume":"48","author":"Zhao L","year":"2003","unstructured":"Zhao L, Takano Y, Horiuchi H. Effect of febuxostat, a novel nonpurine, selective inhibitor of xanthine oxidase (NP-SIXO), on enzymes in purine and pyrimidine metabolism pathway. Arthritis Rheum. 2003;48:S531.","journal-title":"Arthritis Rheum"},{"key":"e_1_3_4_41_1","first-page":"307","article-title":"A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase\/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats","volume":"104","author":"Horiuchi H","year":"1999","unstructured":"Horiuchi H, Ota M, Kobayashi M, et al. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase\/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats. Res Commun Mol Pathol Pharmacol. 1999;104:307\u2013319.","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90201-R"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X16646703"},{"key":"e_1_3_4_44_1","unstructured":"FDA drug safety communication: FDA to evaluate increased risk of heart-related death and death from all causes with the gout medicine febuxostat (Uloric). [cited 2020 Apr 24]. Available from: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm584702.htm"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1021\/jf102689k"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1021\/jf505584m"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2015.08.017"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.5b03386"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867023371229"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2010.12.009"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2017.01.056"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114515005310"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00363a004"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2003.12.010"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2015.12.006"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.13114"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2015.08.056"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2015.01.055"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.12686"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1039\/C6RA24651F"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.09.051"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.06.009"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c15-00282"},{"key":"e_1_3_4_64_1","first-page":"145","article-title":"Microwave assisted synthesis of some 5-substituted imidazolone analogs as a new class of non purine xanthine oxidase inhibitors","volume":"7","author":"Chopra B","year":"2015","unstructured":"Chopra B, Dhingra AK, Kapoor RP, et al. Microwave assisted synthesis of some 5-substituted imidazolone analogs as a new class of non purine xanthine oxidase inhibitors. Der Pharma Chem. 2015;7:145\u2013152.","journal-title":"Der Pharma Chem"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573406410666150807111336"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-015-1382-0"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.3109\/14756366.2014.961446"},{"key":"e_1_3_4_68_1","first-page":"127","article-title":"Synthesis, screening and docking studies of benzochromone derivatives as xanthine oxidase inhibitors","volume":"7","author":"Charanjeet K","year":"2015","unstructured":"Charanjeet K, Suruchi D, Harbinder S, et al. Synthesis, screening and docking studies of benzochromone derivatives as xanthine oxidase inhibitors. J Chem Pharm Res. 2015;7:127\u2013136.","journal-title":"J Chem Pharm Res"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.03.002"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2017.12.017"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1039\/C8MD00512E"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103564"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112077"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.201601438"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phytol.2015.03.005"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2017.01.016"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21030302"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodres.2016.07.021"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.6b03339"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2015.10.022"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2015.08.017"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.04.048"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/825792"},{"key":"e_1_3_4_84_1","unstructured":"Baylor College of Medicine. Small molecule xanthine oxidase inhibitors and methods of use. US2015004699A1. 2015."},{"key":"e_1_3_4_85_1","unstructured":"Atom Bioscience and Pharmaceutical Co Ltd. 2-Aryl selenazole compound and pharmaceutical composition thereof. US2015291543A1. 2015."},{"key":"e_1_3_4_86_1","unstructured":"Teijin Pharma Limited. Azole benzene derivative. US2015376174A1. 2015."},{"key":"e_1_3_4_87_1","unstructured":"Teijin Pharma Limited. Crystal of azole benzene derivative. EP3176165A1. 2017."},{"key":"e_1_3_4_88_1","unstructured":"Warrell R. Methods for reducing uric acid levels using barbiturate derivatives. WO2015073317A1. 2015."},{"key":"e_1_3_4_89_1","unstructured":"Warrell R Bifunctional compounds and use for reducing uric acid levels. WO2016118611A1. 2016."},{"key":"e_1_3_4_90_1","unstructured":"Acquist LLC. Compounds and their use for reducing uric acid levels. WO2018005192A1. 2018."},{"key":"e_1_3_4_91_1","unstructured":"Acquist LLC. Bifunctional compounds and use for reducing uric acid levels. US10093631B2. 2018."},{"key":"e_1_3_4_92_1","unstructured":"Suntory Holdings Limited. Uric acid level lowering agent. EP3159005A1. 2017."},{"key":"e_1_3_4_93_1","unstructured":"Food Industry Research and Development Institute. Use of beta-carboline alkaloid in inhibiting xanthine oxidase activity. US2017165239A1. 2017."},{"key":"e_1_3_4_94_1","first-page":"442","article-title":"Metabolites of salvianolic acid C in rats in vivo","volume":"44","author":"Yan Y","year":"2013","unstructured":"Yan Y, Changjiangsheng LAI, Ping LI, et al. Metabolites of salvianolic acid C in rats in vivo. J China Pharm Univ. 2013;44:442\u2013446.","journal-title":"J China Pharm Univ"},{"key":"e_1_3_4_95_1","unstructured":"China Pharmaceutical University. A type of aryl benzofuran amidated derivative and medical use thereof. US2019040029A1. 2019."},{"key":"e_1_3_4_96_1","unstructured":"Natreon Inc. Terminalia Chebula and Terminalia Bellerica extracts for inhibition of xanthine oxidase. US2015050369A1. 2015."},{"key":"e_1_3_4_97_1","unstructured":"Korea Institute of Science and Technology. Aster Glehni extracts fractions or compounds isolated therefrom for the treatment or prevention of hyperuricemia or gout. US2015337001A1. 2015."},{"key":"e_1_3_4_98_1","unstructured":"Korea Institute of Oriental Medicine. Anti-gout composition containing mixture extract of Chrysanthemum indicum and Cinnamomum cassia as active ingredient. EP3238732A2. 2017."},{"key":"e_1_3_4_99_1","unstructured":"TCI Co. Ltd. Method of reducing uric acid with fucoxanthin-containing composition. US20170340598A1. 2017."},{"key":"e_1_3_4_100_1","unstructured":"Huazhong Agricultural University. Method for preparing medicine with dicaffeoylquinic acid for treating gout. US2020000761A1. 2020."},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.50.916"},{"key":"e_1_3_4_102_1","unstructured":"Meiji Co. Ltd. Lactic acid bacterium having effect of lowering blood uric acid level. US2010\/0316618. 2010."},{"key":"e_1_3_4_103_1","unstructured":"Meiji Co. Ltd. Lactic acid bacteria having action of lowering blood uric acid level. US2011\/0014168. 2011."},{"key":"e_1_3_4_104_1","unstructured":"Food Industry Research and Development Institute. Novel Acetobacter and gluconacetobacter strains and their metabolites for use in inhibiting xanthine oxidase. US2016051596A1. 2016."},{"key":"e_1_3_4_105_1","unstructured":"Food Industry Research and Development Institute. Novel strain of Lactobacillus rhamnosus and its metabolites for use in inhibiting xanthine oxidase and treating gout. US2016051602A1. 2016."},{"key":"e_1_3_4_106_1","unstructured":"Clinicaltrials.gov NCT02190786. Phase II exploratory clinical study of KUX-1151. [cited 2020 Apr 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02190786?term=NCT02190786&draw=2&rank=1"},{"key":"e_1_3_4_107_1","unstructured":"Clinicaltrials.gov NCT01361646. Safety tolerability and pharmacokinetic\/pharmacodynamic characteristics of LC350189. [cited 2020 Apr 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01361646?term=NCT01361646&draw=2&rank=1"},{"key":"e_1_3_4_108_1","first-page":"5033","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects","volume":"9","author":"Seonghae Y","year":"2015","unstructured":"Seonghae Y, Donghoon S, Howard L, et al. Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015;9:5033\u20135049.","journal-title":"Drug Des Devel Ther"},{"key":"e_1_3_4_109_1","unstructured":"Clinicaltrials.gov NCT03934099. A study to assess efficay and safety of LC350189 different doses in gout patients with hyperuricemia. [cited 2020 Apr 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=NCT03934099&cntry=&state=&city=&dist="},{"key":"e_1_3_4_110_1","unstructured":"Clinicaltrials.gov NCT02500641. Intensive urate lowering therapy of febuxostat compared to allopurinol on cardiovascular risk in patients with gout. [cited 2020 Apr 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02500641?term=NCT02500641&draw=2&rank=1"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-014-0935-8"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.108.797662"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-018-1599-6"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3474-8"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-019-01811-9"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1271\/bbb.63.1787"},{"key":"e_1_3_4_117_1","unstructured":"Clinicaltrials.gov NCT04161872. Nutraceutical on Hyperuricemia. [cited 2020 Apr 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04161872?term=Quercetin&cond=Hyperuricemia&draw=2&rank=1"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34488"},{"key":"e_1_3_4_119_1","unstructured":"The pharmaceutical benefits scheme. Available from: www.pbs.gov.au\/medicine\/item\/10445R"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40583"},{"key":"e_1_3_4_121_1","unstructured":"FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat). [cited 25 Apr 2020]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-increased-risk-death-gout-medicine-uloric-febuxostat"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2020.1811233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:02:49Z","timestamp":1735776169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2020.1811233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":119,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,2]]}},"alternative-id":["10.1080\/13543776.2020.1811233"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2020.1811233","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}